TY - JOUR
T1 - Do reductions in ghrelin contribute towards antipsychotic-induced weight gain?
AU - Firth, Joseph
AU - Teasdale, Scott B.
AU - Jackson, Sarah E.
AU - Vancampfort, Davy
AU - Siskind, Dan
AU - Sarris, Jerome
AU - Solmi, Marco
PY - 2019
Y1 - 2019
N2 - We read with interest the recent meta-analysis by Goetz and Miller (2018),which reported that circulating levels of ghrelin are significantly reduced by olanzapine treatment. This finding may shed new light on the behavioural and metabolic side-effects of olanzapine, as ghrelin is widely referred to as ‘the hunger hormone’, due to its well-established role in appetite regulation and satiety (Higgins et al., 2007). Somewhat paradoxically, reductions in ghrelin levels are an established risk factor for both binge-eating (Geliebter et al., 2005) and obesity (Tschöp et al., 2001). Indeed, previous research has suggested the drastic weight gain observed in with second-generation antipsychotic treatment may be mediated by increases in appetite (Mayfield et al., 2016). Supporting this, recent population-scale studies have found that individuals with psychotic disorders are not only less active than the general population (Firth et al., 2018b), but also consume substantially more total calories and obesogenic foods (i.e. sugars, carbohydrates, and saturated fats) than people with othermental disorders, even after adjusting for social deprivation and education (Firth et al., 2018a).
AB - We read with interest the recent meta-analysis by Goetz and Miller (2018),which reported that circulating levels of ghrelin are significantly reduced by olanzapine treatment. This finding may shed new light on the behavioural and metabolic side-effects of olanzapine, as ghrelin is widely referred to as ‘the hunger hormone’, due to its well-established role in appetite regulation and satiety (Higgins et al., 2007). Somewhat paradoxically, reductions in ghrelin levels are an established risk factor for both binge-eating (Geliebter et al., 2005) and obesity (Tschöp et al., 2001). Indeed, previous research has suggested the drastic weight gain observed in with second-generation antipsychotic treatment may be mediated by increases in appetite (Mayfield et al., 2016). Supporting this, recent population-scale studies have found that individuals with psychotic disorders are not only less active than the general population (Firth et al., 2018b), but also consume substantially more total calories and obesogenic foods (i.e. sugars, carbohydrates, and saturated fats) than people with othermental disorders, even after adjusting for social deprivation and education (Firth et al., 2018a).
KW - antipsychotic drugs
KW - ghrelin
KW - nutrition
KW - obesity
KW - psychoses
UR - http://handle.westernsydney.edu.au:8081/1959.7/uws:51789
U2 - 10.1016/j.schres.2018.12.043
DO - 10.1016/j.schres.2018.12.043
M3 - Article
SN - 1573-2509
SN - 0920-9964
VL - 210
SP - 301
EP - 302
JO - Schizophrenia Research
JF - Schizophrenia Research
ER -